3 results
Approved WMORecruitment stopped
To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.
Approved WMORecruiting
To increase insight in the glucose metabolism in surgically treated PPGL patients by using dynamic FDG-PET/CT for analysis of tumor metabolic activity, blood fraction and full pharmacokinetic parameters. Furthermore, to correlate these finding with…
Approved WMORecruiting
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…